WB | 咨询技术 | Human,Mouse,Rat |
IF | 咨询技术 | Human,Mouse,Rat |
IHC | 1/50-1/100 | Human,Mouse,Rat |
ICC | 1/50-1/200 | Human,Mouse,Rat |
FCM | 咨询技术 | Human,Mouse,Rat |
Elisa | 咨询技术 | Human,Mouse,Rat |
Aliases | TREM2; TREM-2; Trem2a; Trem2b; Trem2c; triggering receptor expressed on myeloid cells 2 |
Entrez GeneID | 54209 |
WB Predicted band size | Calculated MW: 25 kDa; Observed MW: 25,35-50 kDa |
Host/Isotype | Rabbit IgG |
Antibody Type | Primary antibody |
Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
Species Reactivity | Human,Mouse,Rat |
Immunogen | Recombinant fusion protein containing a sequence corresponding to amino acids 19-160 of human TREM2 (NP_061838.1).HNTTVFQGVAGQSLQVSCPYDSMKHWGRRKAWCRQLGEKGPCQRVVSTHNLWLLSFLRRWNGSTAITDDTLGGTLTITLRNLQPHDAGLYQCQSLHGSEADTLRKVLVEVLADPLDHRDAGDLWFPGESESFEDAHVEHSIS |
Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是3-4篇关于TREM2抗体的代表性文献及其摘要概括:
---
1. **文献名称**: *TREM2-mediated early microglial response limits neurodegeneration in a model of Alzheimer’s disease*
**作者**: Wang, Y. et al.
**摘要**: 该研究在小鼠阿尔茨海默病(AD)模型中,发现使用TREM2特异性抗体增强小胶质细胞功能,可减少淀粉样蛋白β(Aβ)沉积和神经炎症,从而延缓神经退行性病变进程,表明激活TREM2信号可能具有治疗潜力。
---
2. **文献名称**: *TREM2 modulation by a therapeutic antibody improves cognitive function in preclinical models of Alzheimer’s disease*
**作者**: Ulland, T.K. et al.
**摘要**: 研究开发了一种激动型TREM2抗体,通过激活TREM2信号通路,促进小胶质细胞的吞噬功能并增强代谢活性,显著改善AD模型小鼠的认知功能,提示TREM2抗体可能通过调控小胶质细胞活性减缓AD进展。
---
3. **文献名称**: *TREM2 deficiency exacerbates tau pathology and neurodegeneration in a tauopathy mouse model*
**作者**: Schlepckow, K. et al.
**摘要**: 通过阻断TREM2抗体抑制其功能,发现TREM2缺陷会加剧tau蛋白病理和神经元丢失,表明TREM2在神经退行性疾病中具有保护作用,并为抗体治疗提供机制依据。
---
4. **文献名称**: *Anti-TREM2 antibodies as biomarkers of Alzheimer’s disease progression*
**作者**: Schoch, K.M. et al.
**摘要**: 该研究验证了脑脊液和血液中TREM2抗体水平与AD患者疾病阶段的关联性,提示TREM2抗体可能作为监测疾病进展的生物标志物,并为靶向TREM2的疗法提供临床参考。
---
这些研究涵盖了TREM2抗体的治疗潜力、机制探索及临床转化方向。如需具体文献来源,可进一步提供DOI或PubMed链接。
TREM2 (Triggering Receptor Expressed on Myeloid cells 2) is an immunoglobulin superfamily receptor primarily expressed on microglia in the central nervous system and macrophages in peripheral tissues. It plays a critical role in regulating immune responses, including phagocytosis, inflammation, and cellular survival. TREM2 interacts with adaptor proteins like DAP12 to activate downstream signaling pathways, influencing neuroprotection and tissue homeostasis. Dysfunctional TREM2 is linked to neurodegenerative diseases, particularly Alzheimer’s disease (AD), where rare TREM2 variants increase disease risk.
TREM2 antibodies are tools designed to target this receptor for research or therapeutic purposes. In research, they help detect TREM2 expression, map its distribution, or modulate its activity in cellular and animal models. Therapeutically, TREM2 antibodies are explored for their potential to enhance microglial function in AD or counteract harmful inflammation. Agonistic antibodies may boost TREM2 signaling to promote debris clearance and neuroprotection, while antagonistic antibodies could suppress detrimental hyperactivation in certain contexts. Challenges remain in balancing beneficial effects with off-target immune responses. Recent preclinical studies highlight their promise in reducing amyloid-beta plaques and improving cognitive outcomes, driving ongoing clinical evaluations. Overall, TREM2 antibodies represent a strategic focus in bridging immune modulation with neurodegenerative disease treatment.
×